Biological Industries Ltd

What Biological Industries Ltd does

Biological Industries Ltd is a developer and manufacturer of cell culture media and reagents serving biological research, molecular biology, stem cell research, and cell therapy manufacturing customers. The company traces its origins to circa 1979 and is headquartered in Cromwell, United States, with a workforce of 51–100 employees. Following Sartorius's 2019 majority acquisition, the company has operated as a subsidiary within the Sartorius Group, with the standalone website discontinued on 19 September 2024 and operations fully redirected to Sartorius channels.

The product portfolio is built around a foundation of classical cell culture media, supported by laboratory waters and buffers, reagents, and supplements for mammalian cell culture workflows. Higher-value offerings include GMP-grade advanced therapy cell culture media in serum-free, xeno-free, and chemically defined formulations targeting immune and stem cell therapy developers, plus the NutriFreez® cryopreservation and NutriStor® cold storage biopreservation solutions validated for sensitive cells including stem cells, T cells, and PBMCs. The underlying technology is rooted in formulation chemistry and quality-controlled manufacturing rather than in software or data platforms.

Commercially, Biological Industries generates revenue through one-time sales of consumable media and reagents rather than subscription or licensing arrangements. Since 2019, distribution has been channeled through Sartorius's global sales organization, the Sartorius eShop (shop.sartorius.com), and the My Sartorius Portal, which provides account-managed, customer-specific pricing. Pricing is not publicly disclosed. Marketing is conducted through Sartorius corporate channels including product pages, downloadable technical literature, newsletter signup, and social media integration.

Name

Biological Industries Ltd

Legal name

Biological Industries Ltd

Website

https://bioind.com

Company type

Private

Founded year

1979

Operating status

Acquired

Headcount range

51–100 employees

Short description

Biological Industries develops and manufactures cell culture media, reagents, and biopreservation solutions for mammalian cell culture, molecular biology, and cell therapy applications. Following Sartorius's 2019 majority acquisition and 2024 full integration, products are sold globally through Sartorius channels.

Ownership category

akta.pro rank

Product category

Cell Culture Media and Reagents

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH)

Keywords

• Cell culture media
• Mammalian cell culture
• Cryopreservation media
• GMP cell therapy media
• Biopreservation solutions

Headquarters

HQ city

Cromwell

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Cell Culture Media and Reagents Sales: Sale of cell culture media, reagents, supplements, buffers, and biopreservation solutions to biological research and biopharmaceutical manufacturing customers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Biological Industries develops and manufactures cell culture media and reagents for mammalian cell culture and molecular biology applications. Its portfolio spans classical cell culture media, serum-free, xeno-free and chemically defined media, GMP-grade advanced therapy media for cell therapy, and biopreservation solutions such as NutriFreez cryopreservation media and NutriStor cold storage products. Products are sold through the Sartorius e-commerce platform following the 2019 acquisition.

Product overview

Biological Industries, acquired by Sartorius in 2019, is a cell culture media developer and manufacturer with more than 40 years of experience. The portfolio consists of multiple interconnected product lines: Classical Cell Culture Media serves as the foundational offering for mammalian cell culture maintenance; supported by Cell Culture Lab Waters & Buffers and Cell Culture Reagents & Supplements for complete experimental workflow; Cell Therapy Media provides GMP-grade advanced formulations (serum-free, xeno-free, chemically defined) for immune and stem cell therapy applications; and Biopreservation Solutions (NutriFreez® and NutriStor®) enable short-term cold storage and long-term cryopreservation of sensitive cells including stem cells, T cells, and PBMCs.

Differentiator

Problem solved

Functional benefit

Products and services

• Classical Cell Culture Media

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators1 record

Recent moves5 records

Expansion highlights3 records

Direct peers

• Bio-Techne: Provides cell culture reagents, supplements, and media components (including GMP-grade cytokines) used in cell therapy manufacturing. Comparable to BI's reagents/supplements portfolio.
• Corning Life Sciences: Manufactures classical and serum-free cell culture media alongside its broader cell culture consumables portfolio. Comparable to BI in classical media and supplements used in mammalian cell culture.
• Lonza Group: Major manufacturer of cell culture media and a leading supplier of GMP-grade media for cell and gene therapy developers. Directly competes with BI in advanced therapy media formulations.
• Miltenyi Biotec: Offers cell processing and culture solutions for cell and gene therapy manufacturing, including media and cryopreservation reagents that overlap with BI's cell therapy media and biopreservation products.
• FUJIFILM Irvine Scientific: Specializes in cell culture media for cell therapy and assisted reproductive technologies, with a strong GMP manufacturing footprint. Directly comparable to BI's GMP-grade advanced therapy media portfolio.
• STEMCELL Technologies: Supplies cell culture media, reagents, and tools focused on stem cell research and cell therapy development. Highly comparable to BI's stem cell and cell therapy media offerings.
• Cytiva: Supplies cell culture media and reagents as part of its broader bioprocessing portfolio, including media for cell therapy applications. Direct overlap with BI's classical and cell therapy media offerings.

Broad incumbents

• Thermo Fisher Scientific (Gibco): Through its Gibco brand, Thermo Fisher is the dominant global supplier of classical cell culture media, reagents, and GMP-grade media for cell therapy. Closely comparable product portfolio to BI across research and bioprocessing cell culture.
• Merck KGaA (MilliporeSigma): Life science tools giant offering a broad portfolio of cell culture media, reagents, and bioprocessing solutions. Comparable to BI in classical and GMP-grade media products and serves the same research and biopharma customer base.

Emerging players

• CellGenix: Specializes in GMP-grade raw materials and cell culture media for cell and gene therapy manufacturers, including cytokines and media directly comparable to BI's advanced therapy offerings.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/bio_industries
• Facebookfacebook.com/bioind
• LinkedInlinkedin.com/company/biological-industries

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biological Industries Ltd